Intracerebroventricular administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite 1-methyl-4-phenylpyridinium ion (MPP+) decrease dopamine and increase acetylcholine in the mouse neostriatum.
We found that both MPTP and its metabolite MPP+ decrease dopamine and increase acetylcholine content of mouse neostriatum when administered intracerebroventricularly (ICV). These observations support the notion that MPP+ may be the active neurotoxin formed in brain after MPTP administration. They also suggest that cholinergic mechanisms may be a target of the neurotoxin.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000031:analogs & derivatives; D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D002421:Caudate Nucleus / Q000378:metabolism*; D002794:Choline / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D011699:Putamen / Q000378:metabolism*; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology*
D011725:Pyridines; C040846:4-phenyl-1,2,3,6-tetrahydropyridine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D002794:Choline; D000109:Acetylcholine; D004298:Dopamine